Aminophylline
Brand names: Phyllocontin
Aminophylline is a soluble salt of theophylline used as a bronchodilator in acute severe asthma and chronic obstructive pulmonary disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a methylxanthine that inhibits phosphodiesterase and antagonises adenosine receptors, relaxing bronchial smooth muscle and enhancing respiratory function.
Prescribing in practice
- It has a narrow therapeutic index with a risk of arrhythmias and convulsions, and serum theophylline concentrations must guide dosing.
- Numerous drug interactions and factors such as smoking, heart failure and hepatic impairment markedly alter clearance.
- Loading regimens differ in patients already taking oral theophylline, so prior therapy must be established before intravenous loading.
Monitoring
Monitor serum theophylline concentrations, heart rate and rhythm, and serum potassium, particularly during intravenous use.
Counselling the patient
- Report palpitations, persistent vomiting, tremor or seizures promptly.
- Tell clinicians if your smoking habits change as this alters how the drug is handled.
- Do not change brands or formulations without advice.
Evidence & guidelines
Therapeutic drug monitoring of theophylline is well established owing to its narrow margin between effective and toxic concentrations.
Reference: BTS/SIGN Asthma 2023; NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024